Corrigendum to “Telmisartan ameliorates cisplatin-induced nephrotoxicity by inhibiting MAPK mediated inflammation and apoptosis” [Eur. J. Pharmachol. 748 (2015) 50–60](S0014299914008668)(10.1016/j.ejphar.2014.12.008);Telmisartan ameliorates cisplatin-induced nephrotoxicity by inhibiting MAPK mediated inflammation and apoptosis

European Journal of Pharmacology

Volumn 748, Issue , 2015, Pages 54-60

  Malik, Salma ^a   Suchal, Kapil ^a   Gamad, Nanda ^a   Dinda, Amit Kumar ^a   Arya, Dharamvir Singh ^a   Bhatia, Jagriti ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

ERK1 2; JNK; Oxidative stress; p38; TNF

Indexed keywords

CISPLATIN; MITOGEN ACTIVATED PROTEIN KINASE; TELMISARTAN; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE KIDNEY TUBULE NECROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME INHIBITION; HISTOPATHOLOGY; INFLAMMATION; MALE; NEPHROTOXICITY; NONHUMAN; OXIDATION REDUCTION STATE; RAT; RENAL PROTECTION; ANIMAL; BLOOD; CELL PROTECTION; DRUG EFFECTS; ENZYME ACTIVATION; KIDNEY; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; WISTAR RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZIMIDAZOLES; BENZOATES; CISPLATIN; CYTOPROTECTION; ENZYME ACTIVATION; INFLAMMATION; KIDNEY; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; OXIDATIVE STRESS; RATS; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84920129588     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2015.08.009     Document Type: Erratum

References (31)

1. H. Aebi Catalase in vitro Methods Enzymol. 105 1984 121 126
2. M.A. Ahmed Effect of angiotensin II type 1 receptor blocker on renal function, arterial blood pressure and parathyroid hormone related protein over expression in cadmium induced nephrotoxicity in adult male rats Int. J. Physiol. Pathophysiol. Pharmacol 5 2013 109 119
3. P. Aranda, J. Segura, L.M. Ruilope, F.J. Aranda, M.A. Frutos, V. López, and Novales E. López de Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies Am. J. Kidney Dis. 46 2005 1074 1079
4. I. Arany, and R.,L. Safirstein Cisplatin nephrotoxicity Semin. Nephro 23 2003 460 464
5. A.H. Barnett Preventing renal complications in diabetic patients: the diabetics exposed to telmisartan and enalaprIL (DETAIL) study Acta Diabetol. 42 2005 S42 S49
6. M.M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal. Biochem 72 1976 248 254
7. J. Deng, Y. Kohda, H. Chiao, Y. Wang, X. Hu, S.M. Hewitt, T. Miyaji, P. McLeroy, B. Nibhanupudy, S. Li, and R.A. Star Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury Kidney Int. 60 2001 2118 2128
8. S.B. Duan, Y.H. Wang, F.Y. Liu, X.Q. Xu, P. Wang, Q. Zou, and Y.M. Peng The protective role of telmisartan against nephrotoxicity induced by X-ray contrast media in rat model Acta Radiol. 50 2009 754 759
9. A.A. Fouad, and I. Jresat Protective effect of telmisartan against cadmium-induced nephrotoxicity in mice Life Sci. 89 2011 29 35
10. A.A. Fouad, H.A. Qureshi, A.I. Al-Sultan, M.T. Yacoubi, and W.N. Al-Melhim Nephroprotective effect of telmisartan in rats with ischemia/reperfusion renal injury Pharmacology 85 2010 158 167
11. H.D. Francescato, R.S. Costa, F.B. Júnior, and T.M. Coimbra Effect of JNK inhibition on cisplatin-induced renal damage Nephrol. Dial. Transplant. 22 2007 2138 2148
12. H.D. Francescato, R.S. Costa, C.G. da Silva, and T.M. Coimbra Treatment with a p38 MAPK inhibitor attenuates cisplatin nephrotoxicity starting after the beginning of renal damage Life Sci. 84 2009 590 597
13. N. Hadi, N.G. Yousif, F.G. Al-amran, N.K. Huntei, B.I. Mohammad, and S.J. Ali Vitamin E and telmisartan attenuates doxorubicin induced cardiac injury in rat through down regulation of inflammatory response BMC Cardiovasc. Disord 12 2012 63
14. M.M. Helmy, M.W. Helmy, D.M. Abd Allah, A.M. Abo Zaid, and M.M. Mohy El-Din Selective ET(A) receptor blockade protects against cisplatin-induced acute renal failure in male rats Eur. J. Pharmacol. 730 2014 133 139
15. M.A. Ibrahim, O.M. Ashour, Y.F. Ibrahim, H.I. El-Bitar, W. Gomaa, and S.R. Abdel-Rahim Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity Pharmacol. Res. 60 2009 373 381
16. S.K. Jo, W.Y. Cho, S.A. Sung, H.K. Kim, and N.H. Won MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis Kidney Int. 67 2005 458 466
17. H.J. Kim, K. Ravichandran, A. Ozkok, Q. Wang, Z. He, A. Jani, D. Ljubanovic, I.S. Douglas, and C.L. Edelstein The water-soluble triptolide derivative PG490-88 protects against cisplatin-induced acute kidney injury J. Pharmacol. Exp. Ther. 349 2014 518 525
18. M. Kruidering, B. Van de Water, E. de Heer, G.J. Mulder, and J.F. Nagelkerke Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain J. Pharmacol. Exp. Ther. 280 1997 638 649
19. S. Kushwaha, and G.B. Jena Telmisartan ameliorates germ cell toxicity in the STZ-induced diabetic rat: studies on possible molecular mechanisms Mutat. Res. 755 2013 11 23
20. S. Marklund, and G. Marklund Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase Eur. J. Biochem. 47 1974 469 474
21. M.S. Moron, J.W. Depierre, and B. Mannervik Levels of glutathione, glutathione reductase and glutathione-s-transferase activities in rat lung and liver Biochim. Biophys. Acta 582 1979 67 78
22. G. Nowak Protein kinase C-alpha and ERK1/2 mediate mitochondrial dysfunction, decreases in active Na+ transport, and cisplatin-induced apoptosis in renal cells J. Biol. Chem. 277 2002 43377 43388
23. H. Ohkawa, N. Ohishi, and K. Yagi Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction Anal. Biochem. 95 1979 351 358
24. T. Ohmura, I. Tsunenari, R. Seidler, M. Chachin, T. Hayashi, A. Konomi, T. Matsumaru, T. Sumida, N. Hayashi, and Y. Horie Renoprotective effects of telmisartan on renal injury in obese Zucker rats Acta Diabetol. 49 2012 S15 S24
25. N. Pabla, and Z. Dong Cisplatin nephrotoxicity: mechanisms and renoprotective strategies Kidney Int. 73 2008 994 1007
26. G. Ramesh, and W.B. Reeves Cisplatin increases TNF-alpha mRNA stability in kidney proximal tubule cells Ren. Fail. 28 2006 583 592
27. G. Ramesh, and W.B. Reeves p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice Am. J. Physiol. Renal Physiol 289 2005 F166 F174
28. S. Takai, K. Kirimura, D. Jin, M. Muramatsu, K. Yoshikawa, Y. Mino, and M. Miyazaki Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling Hypertens. Res. 28 2005 593 600
29. Y. Terada, K. Inoue, T. Matsumoto, M. Ishihara, K. Hamada, Y. Shimamura, K. Ogata, K. Inoue, Y. Taniguchi, T. Horino, T. Karashima, K. Tamura, H. Fukuhara, S. Fujimoto, M. Tsuda, and T. Shuin 5-Aminolevulinic acid protects against cisplatin-induced nephrotoxicity without compromising the anticancer efficiency of cisplatin in rats in vitro and in vivo PLoS One 8 2013 e80850
30. I. Tsunenari, T. Ohmura, R. Seidler, M. Chachin, T. Hayashi, A. Konomi, T. Matsumaru, T. Sumida, N. Hayashi, and Y. Horie Renoprotective effects of telmisartan in the 5/6 nephrectomised rats J. Renin Angiotensin Aldosterone Syst 8 2007 93 100
31. A. Yonezawa, S. Masuda, K. Nishihara, I. Yano, T. Katsura, and K. Inui Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat Biochem. Pharmacol. 70 2005 1823 1831